Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Transition to a mesenchymal state in neuroblastoma confers resistance to anti-GD2 antibody via reduced expression of ST8SIA1
Nathaniel W. Mabe, Min Huang, Guillermo Nicolás Dalton, et al.
Nature Cancer (2022) Vol. 3, Iss. 8, pp. 976-993
Open Access | Times Cited: 61

Showing 1-25 of 61 citing articles:

Pharmacological targeting of the cancer epigenome
Nathaniel W. Mabe, Jennifer A. Perry, Clare F. Malone, et al.
Nature Cancer (2024) Vol. 5, Iss. 6, pp. 844-865
Closed Access | Times Cited: 19
ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells
Elisa Bergaggio, Wei‐Tien Tai, Andrea Aroldi, et al.
Cancer Cell (2023) Vol. 41, Iss. 12, pp. 2100-2116.e10
Open Access | Times Cited: 32
Biology of GD2 ganglioside: implications for cancer immunotherapy
Pierre Machy, Erwan Mortier, Stéphane Birklé
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 26
GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma
Roselia Ciccone, Concetta Quintarelli, Antonio Camera, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 11, pp. 2545-2557
Open Access | Times Cited: 14
Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers
Lena Fischer‐Riepe, Sareetha Kailayangiri, Katharina Zimmermann, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 16, pp. 3564-3577
Open Access | Times Cited: 10
Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors
Yasuyuki Matsumoto, Tongzhong Ju
Cancers (2023) Vol. 15, Iss. 14, pp. 3536-3536
Open Access | Times Cited: 21
Identification and characterization of chemotherapy resistant high-risk neuroblastoma persister cells
Liron D. Grossmann, Chia-Hui Chen, Yasin Uzun, et al.
Cancer Discovery (2024), pp. OF1-OF20
Open Access | Times Cited: 7
Bioactive sphingolipids as emerging targets for signal transduction in cancer development
Wentao Jia, Jiaying Yuan, Jinbo Zhang, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2024) Vol. 1879, Iss. 5, pp. 189176-189176
Closed Access | Times Cited: 7
Noninvasive serum N-glycans associated with ovarian cancer diagnosis and precancerous lesion prediction
Si Liu, Chang Tu, Haobo Zhang, et al.
Journal of Ovarian Research (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 6
Novel insights on genetics and epigenetics as clinical targets for paediatric astrocytoma
D. Johns, Richard J. Williams, Craig M. Smith, et al.
Clinical and Translational Medicine (2024) Vol. 14, Iss. 2
Open Access | Times Cited: 4
Lineage-dependence of the neuroblastoma surfaceome defines tumor cell state-dependent and independent immunotherapeutic targets
Nathan M. Kendsersky, Michal Odrobina, Nathaniel W. Mabe, et al.
Neuro-Oncology (2025)
Open Access
Predictive role of SLC1A5 in neuroblastoma prognosis and immunotherapy
Jian Cheng, Miaomiao Sun, Dong Xiao, et al.
BMC Cancer (2025) Vol. 25, Iss. 1
Open Access
Longitudinal single-cell multiomic atlas of high-risk neuroblastoma reveals chemotherapy-induced tumor microenvironment rewiring
Wenbao Yu, Rumeysa Biyik‐Sit, Yasin Uzun, et al.
Nature Genetics (2025)
Open Access
A drug that induces the microRNA miR-124 enables differentiation of retinoic acid–resistant neuroblastoma cells
Lien D. Nguyen, Satyaki Sengupta, Kevin I. Cho, et al.
Science Signaling (2025) Vol. 18, Iss. 882
Closed Access
Hopes on immunotherapy targeting B7-H3 in neuroblastoma
Rafael Pulido, Caroline E. Nunes‐Xavier
Translational Oncology (2022) Vol. 27, pp. 101580-101580
Open Access | Times Cited: 18
Global Impact of Monoclonal Antibodies (mAbs) in Children: A Focus on Anti-GD2
Cristina Larrosa, Jaume Mora, Nai‐Kong V. Cheung
Cancers (2023) Vol. 15, Iss. 14, pp. 3729-3729
Open Access | Times Cited: 9
Silencing of the PHLDA1 leads to global proteome changes and differentiation pathways of human neuroblastoma cells
Beata Bugara, Małgorzata Durbas, M. Kudrycka, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 3
Review: Targeting EZH2 in neuroblastoma
Jinhui Gao, Claire Fosbrook, Jane Whitney Gibson, et al.
Cancer Treatment Reviews (2023) Vol. 119, pp. 102600-102600
Open Access | Times Cited: 9
The yes-associated protein (YAP) is associated with resistance to anti-GD2 immunotherapy in neuroblastoma through downregulation of ST8SIA1
Adeiye A. Pilgrim, Hunter C. Jonus, Andrew K.S. Ho, et al.
OncoImmunology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 8
Naxitamab Activity in Neuroblastoma Cells Is Enhanced by Nanofenretinide and Nanospermidine
Lucrezia Galassi, Martina Rossi, Pietro Lodeserto, et al.
Pharmaceutics (2023) Vol. 15, Iss. 2, pp. 648-648
Open Access | Times Cited: 7
Adrenergic and mesenchymal signatures are identifiable in cell‐free DNA and correlate with metastatic disease burden in children with neuroblastoma
Omar R. Vayani, Maria E. Kaufman, Kelley Moore, et al.
Pediatric Blood & Cancer (2023) Vol. 71, Iss. 1
Open Access | Times Cited: 7
Mutually exclusive teams-like patterns of gene regulation characterize phenotypic heterogeneity along the noradrenergic-mesenchymal axis in neuroblastoma
Manas Sehgal, Sonali Nayak, Sarthak Sahoo, et al.
Cancer Biology & Therapy (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 2
Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells
Sabina Di Matteo, Maria Teresa Bilotta, Andrea Pelosi, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 2
USP44 Overexpression Drives a MYC-Like Gene Expression Program in Neuroblastoma through Epigenetic Reprogramming
Thomas L. Ekstrom, Sajjad Hussain, Tibor Bedekovics, et al.
Molecular Cancer Research (2024) Vol. 22, Iss. 9, pp. 812-825
Closed Access | Times Cited: 2
Identification and validation of sialyltransferase ST3Gal5 in bladder cancer through bioinformatics and experimental analysis
Yuli Jian, Qiwei Chen, Abdullah Al-Danakh, et al.
International Immunopharmacology (2024) Vol. 138, pp. 112569-112569
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top